Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies, and RNA or DNA based therapies. Celsion has three platform technologies for development of novel nucleic, acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including LTSL, TheraPlas™, and TheraSilence™.

Michael H. Tardugno
Chairman, President & Chief Executive Officer


Khursheed Anwer, PhD, MBA
Executive Vice President & Chief Scientific Officer


Nicholas Borys, MD
Senior Vice President & Chief Medical Officer


Jeffrey W. Church
Senior Vice President & Chief Financial Officer


Jason Fewell, PhD
Vice President, Preclinical Research

All resident associate companies on the HudsonAlpha campus are independently owned and operated.